Drug intelligence / Profile preview

ONO-7746

Development stage: Phase 1
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ONO-7746 is an orally available small molecule and thrombopoietin (TPO) receptor agonist developed to stimulate megakaryopoiesis and increase platelet production. By activating the TPO receptor (also known as c-Mpl or MPL), ONO-7746 promotes the proliferation and differentiation of megakaryocyte progenitor cells, leading to increased platelet counts. It is being investigated primarily for the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets that increases bleeding risk. The drug was co-developed by Ono Pharmaceutical and Nissan Chemical Industries[1][2][5][7].

Other names: Blood clotting modulator NissanPeptidomimetic thrombopoietin agonist

Targets

TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on ONO-7746.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-7746.

Explore the full profile